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Abstract
TGFβ induces hepatocyte apoptosis via reactive oxygen species (ROS) generation, the mitochondrial
permeability transition (MPT), and caspase activation. The role of the Smad pathway in these events
is unknown. In this study primary hepatocytes were isolated from Smad3 wild-type (+/+) and
knockout (−/−) mice, and were treated with TGFβ (5 ng/ml) and/or trolox (2 mM). ROS generation,
MPT, TGFβ-dependent transcription, and apoptosis were assessed in the presence or absence of
Smad3 wild-type (WT) and dominant-negative (DN) plasmids. With TGFβ treatment, Smad3 (−/−)
hepatocytes did not generate ROS activity, exhibit MPT, activate caspases, or undergo apoptosis
when compared to Smad 3 (+/+) hepatocytes. Similarly, transfection of Smad3 (+/+) hepatocytes
with DN-Smad3 inhibited TGFβ-mediated transcription, ROS generation, MPT, and apoptosis.
However, Smad3 (−/−) cells transfected with WT-Smad3 and treated with TGFβ demonstrated
increased transcriptional activity, the MPT, and TGFβ-induced apoptosis. TGFβ-mediated ROS
generation occurred through an NADPH–like oxidase pathway since diphenyleneiodonium chloride
inhibited ROS induction. In conclusion, TGFβ-induced hepatocyte apoptosis occurs through Smad3
dependent activation of ROS with subsequent activation of the MPT and caspases.
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Transforming growth factor beta 1 (TGFβ) is a multifunctional cytokine, which mediates
hepatocellular differentiation, growth, and apoptosis [1]. After partial hepatectomy, TGFβ has
an integral role in terminating liver regeneration secondary to its hepatocyte anti-proliferative
effects. In vitro and in vivo studies have also shown that TGFβ controls hepatocyte growth
directly by inducing apoptosis [2-4]. Furthermore, TGFβ-induced apoptosis occurs through
ROS generation, the mitochondrial permeability transition (MPT), and caspase activation [5].
Moreover, Smad3-dependent cleavage of the mitochondrial, pro-apoptotic protein, BAD,
results in TGFβ-induced apoptosis in FaO hepatoma cells and suggests a distinct role for Smad3
[2]. Thus, these findings suggest that the TGFβ apoptotic pathway includes ROS generation,
Smad3 activation, mitochondria involvement, and caspase cleavage.
Several mechanisms by which Smad3 initiates cell death signals have been examined in a
number of studies. GADD45β has been identified as a Smad-dependent, early response
mediator of TGFβ-induced apoptosis [6]. In this study, AML12 murine hepatocytes underwent
apoptosis in response to GADD45β activation of p38. Furthermore, GADD45β activation was
dependent on Smad2, Smad3, and Smad4 activation of the proximal portion of the
GADD45β promoter [6]. Additional studies have also identified a TGFβ-responsive enhancer
in the third intron of GADD45β [7]. The enhancer is responsive to Smad3 and Smad4, but not
Smad2. Collectively, these studies show that GADD45β expression is mediated at multiple
genetic loci, and is an important Smad-dependent mediator of TGFβ-induced apoptosis that is
affected through p38 expression. In addition, Smad3 regulates hepatocyte responsiveness to
apoptosis by the down-regulation of the anti-apoptotic protein, Bcl-2 [8]. In a mouse model of
carcinogen-induced hepatocellular cancer, forced expression of Smad3 decreased expression
of Bcl-2 with resultant apoptosis and decreased cancer cell formation. Interestingly, this study
also showed that expression of p38 was required for apoptosis. Furthermore, Akt has been
identified as an integral regulator of Smad3 phosphorylation and, subsequently, TGFβ-
mediated apoptosis [9]. Akt sequestered unphosphorylated Smad3 in the cytoplasm and, thus
inhibited nuclear translocation and transcription, ultimately decreasing TGFβ-induced
apoptosis. The ratio of Smad3 to Akt is an important mechanism that controls TGFβ-induced
apoptosis, but not growth inhibition.
In addition to altering effector signaling pathways, TGFβ also induces ROS. Both early [5]
and late activation of ROS in response to TGFB have been identified [10;11]. In lung
fibroblasts, TGFβ induced NADH oxidase production of hydrogen peroxide begins 8 hours
after treatment with peak activity at 16 hours [10]. Additionally, Sanchez et al. demonstrated
that TGFβ induced ROS occurred 4 hours after TGFβ stimulation in fetal rat hepatocytes
[11]. Both studies demonstrated that ROS generation was dependent on new protein synthesis.
Other studies have demonstrated that early (90 minutes) activation of ROS is important for
TGFβ-induced apoptosis [5]. However, no study has demonstrated the importance of Smad
activation in ROS generation following TGFβ stimulation. Moreover, a recent investigation
of hepatocyte specific deletion of Smad2 suggests that this TGFβ-induced protein is not
required for apoptosis [12].
Although Smad proteins have been associated with TGFβ-induced hepatocyte growth control,
the relationship between ROS generation and activation of Smad proteins has not been
examined. Importantly, how ROS and Smad3 affect TGFβ-induced apoptosis has not been
determined. The purpose of this study was to determine if Smad3 and ROS are required for
TGFβ-induced apoptosis, and, if so, how these signaling factors influence TGFβ-induced cell
death. Herein, the role of Smad3 in the TGFβ apoptotic pathway was determined in Smad3
wild-type (+/+) and knockout (−/−) primary murine hepatocytes by evaluating the mediators
of the apoptotic pathway: ROS, MPT, and caspase activation.
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2. Materials and Methods
2.1 Hepatocyte Harvest and Culture
Smad3 (+/+) and Smad3 (−/−) mice were kindly obtained from David Brenner, M.D. [13].
These Smad3 deficient mice have a deletion in exon 1 of the Smad3 gene [14]. Hepatocytes
from Smad3 (+/+) and Smad3 (−/−) mice were isolated by retrograde collagenase perfusion
[15]. Briefly, the liver was perfused with 100 ml of Krebs-Ringer-Hepes (KRH) buffer
containing 0.25 M HEPES, 115 mM NaCl, 50 mM KCl, 10 mM KH2PO4, and 0.5 mM EGTA
at pH 7.4. A collagenase buffer (200 ml) containing 1 mM CaCl2 and 0.4 mg/ml type 1
collagenase was perfused into the liver. The liver was excised and gently combed to manually
disperse hepatocytes. Hepatocytes were then selected by differential centrifugation. Cell
viability was assessed by trypan blue exclusion (>90% for experiments). Hepatocytes were
plated in Waymouth's media supplemented with 10% fetal calf serum, 5 μg/ml insulin, and
100 nmol/L dexamethasone for four hours. The medium was changed overnight to a serum-
free, hormonally-defined medium (HDM) consisting of RPMI 1640 containing insulin (5 μg/
ml), transferrin (5 μg/ml), selenium (3 μM), and free fatty acid (1.5 μM). Subsequent hepatocyte
experiments were performed under these conditions.
In select experiments, hepatocytes were pretreated with trolox (2 mM), actinomycin D (1 μg/
ml), cycloheximide, (10 mg/ml) or diphenyleneiodonium chloride (DPI; 1 mM) before TGFβ
(5 ng/ml) or tumor necrosis factor alpha (TNFα; 30 ng/ml) treatment was initiated.
2.2 JAR Cell Culture
Smad3 deficient JAR cell line was purchased from ATCC (HTB-144) and cultured in RPMI
1640 medium containing 2 mM L-glutamine, 17.8 mM NaHCO3, 30 mM glucose, 10 mM
HEPES, 1 mM sodium pyruvate, and 10% fetal bovine serum in humidified 5% CO2 / 95% air
at 37°C [16].
2.3 Morphologic Assessment of Apoptosis
Hepatocytes were fixed and permeabilized in a 3:1 methanol/acetic acid for 10 minutes at 4°
C, and stained with 2 mg/ml propidium iodide (PI) following 0, 24, 36, and 48 hours of
incubation with TGFβ. Hepatocytes were visualized under green UV light using an IX-70
Olympus microscope (Olympus, Tokyo, Japan), and the number of condensed nuclei indicative
of apoptotic hepatocytes was quantified in 5 high powered fields (hpf) at 400× magnification
[17].
2.4 Caspase-3 and Caspase-8 Activity
As described previously, caspase-3 and caspase-8 activities were determined with the
substrates DETD-AFC and LEVD-AFC, respectively, by fluorometric analysis on a Perkin
Elmer Luminescence Spectrometer LS50B (Perkin Elmer; Norwalk, CT) [3]. Hepatocytes
were plated at a density of 1.5 × 106 in a 60 mm dish and lysed in a 1× lysis buffer (10 mM
HEPES, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 1 mM PMSF, 10 μg/ml pepstatin A, 10
μg/ml aprotinin, 20 μg/ml leupeptin) by five rapid freeze/thaw cycles. Lysates were incubated
in the dark at 37°C for four hours with 25 μM of the caspase substrate. The rate of caspase
cleavage was determined by a standard curve, and then normalized for protein concentration.
2.5 Reactive Oxygen Species Activity
Hepatocytes and JAR cells were plated at 1.8 × 105 per well in a 12-well plate, rinsed with
PBS, and incubated with 10 μM 2',7'-dichlorodihydrofluorescein diacetate (Molecular Probes,
Eugene, OR) for 20 minutes at 37°C in the presence of TGFβ (5 ng/ml), trolox (2 mM),
actinomycin D (1 μg/ml), and/or cycloheximide (10 mg/ml). Fluorescence activity was
Black et al. Page 3













determined on a fluormetric BMG Labtechnologies plate reader (Durham, NC) with a gain of
30 nm and 529 nm emission and 485 nm excitation wavelengths, respectively.
2.6 Mitochondrial Permeability Transition (MPT)
The MPT was assessed by confocal microscopy with the dyes tetramethylrhodamine methyl
ester (250 nM; TMRM, Molecular Probes) and calcein (1 μM Molecular Probes) as described
previously [5]. Hepatocytes (1 × 106 in a 60 mm dish) plated on collagen-coated coverslips
were loaded with the dyes for 20 minutes at 37°C, and then rinsed with PBS. Calcein and
TMRM fluorescence was captured with an argon laser at 488 nm and 568 nm, respectively,
using a 60× objective.
2.7 Plasmid Transient Transfections
Hepatocytes were plated at 1.8 × 105 per well on 6-well plates, and transfection with 1 μg DNA
accomplished with 2.5 μl of Targafect F-1 (Targeting Systems, San Diego, CA) in 1 ml Opti-
Mem1 (or DMEM for apoptosis experiments) for 2 hours. We assessed transfection efficiency
using Targafect F-1 and a GFP expressing plasmid with 30% transfection efficiency.
Full-length human FLAG-tagged Smad3 and dominant negative Smad3 cloned into a pRK5
vector were generous gifts from Dr. Xing Zhang (UCSF and Genentech, South San Francisco,
CA). DN-Smad3 is truncated at the carboxy terminus. The polylinker region of pcDNA3.1(-)
(Invitrogen, Carlsbad, CA) was modified to introduce a unique ClaI site by inserting a novel
oligonucleotide pair with BamHI and HindIII overhangs into the BamHI and HindIII sites. The
sequences of the oligonucleotides were as follows: 5' GAT CCG CAA TCG ATG CAG CAA
3'. The oligos were annealed at 65°C for 10 minutes and ligated into the BamHI and HindIII
digested vector. FLAG-tagged Smad3 in pRK5 was digested with ClaI and HindIII, gel purified
and cloned into the ClaI/HindIII digested vector. FLAG-tagged DN-Smad3 in pRK5 was
digested with EcoRI and HindIII, gel purified and cloned into the EcoRI/HindIII digested
pcDNA3.1.
2.8 Transcriptional Activity
TGFβ-induced transcriptional activity was assessed with the luciferase assay system (Promega,
Madison, WI) by transiently transfecting the p3TP-luciferase reporter plasmid containing
multiple Smad binding elements in the promoter region. Hepatocytes were treated with
TGFβ for 24 hours and luciferase activity was assessed via a luminometer.
2.9 Statistical Analysis
Each experiment was performed with hepatocytes from a minimum of three mice. Assays were
performed in triplicate. Outcomes are reported as the mean plus or minus the standard error of
the mean. Statistical analysis was determined using the Student's t-test and significance was
set at p<0.05.
3. Results
3.1 Smad3 (−/−) Hepatocytes Resist TGFβ-Induced Apoptosis
To determine the necessity of Smad3 in TGFβ-induced apoptosis, Smad3 (+/+) and Smad3 (−/
−) hepatocytes were treated with or without TGFβ for 48 hours, and apoptosis was assessed
by PI stain. After 48 hours of treatment, 43% ± 0.06% of Smad3 (+/+) hepatocytes had
morphologic evidence of apoptosis (Fig. 1A & 1B). However, Smad3 (−/−) hepatocytes treated
with TGFβ showed only 7.6% ± 0.01% apoptosis (p<0.05), which was similar to untreated
Smad3 hepatocytes (Fig. 1A & 1B).
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Caspase-3 and caspase-8 activities were measured to confirm TGFβ-induced apoptosis in
Smad3 (+/+) hepatocytes, and to assess caspase activation in Smad3 (−/−) hepatocytes. Smad3
(+/+) hepatocytes treated with TGFβ had a 3.4-fold ± 1.2 increase (p<0.05) in caspase-3 activity
at 36 hours as compared to untreated Smad3 (+/+) hepatocytes (Fig. 1C). Smad3 (−/−)
hepatocytes did not generate caspase-3 activity over control values following treatment with
TGFβ, thus confirming the lack of caspase-induced apoptosis (Fig. 1C). Similarly, caspase-8
activity was increased in Smad3 (+/+) hepatocytes with a 1.7-fold ± 0.41 increase at 36 hours
as compared to the control treated Smad3 (+/+) hepatocytes. Smad3 (−/−) hepatocytes had no
caspase-8 activity induction with TGFβ treatment as compared to untreated controls (Fig. 1C).
These findings suggest that Smad3 (−/−) hepatocytes do not undergo apoptosis in response to
TGFβ treatment because of lack of activation of the caspase pathway.
To determine if Smad3 (−/−) hepatocyte resistance to apoptosis was specific to TGFβ, we
treated Smad3 (+/+) and Smad3 (−/−) hepatocytes with TNFα following inhibition of NFκB
with actinomycin D. Both Smad3 (+/+) and Smad3 (−/−) hepatocytes were susceptible to
TNFα-induced apoptosis. At 12 hrs, TNFα/ActD-treated Smad3 (+/+) hepatocytes showed
50.9% ± 13.3% apoptosis versus 8.4% ± 4.2% for untreated controls, and Smad3 (−/−)
hepatocytes exhibited 46.3% ± 13% apoptosis versus 5.7% ± 1.7% for untreated controls (Fig.
1D). These findings suggest that the requirement for Smad3 is specific for TGFβ-induced
hepatocyte apoptosis.
Typically, TGFβ causes hepatocyte MPT prior to apoptosis [5]. In these experiments, MPT
was assessed by confocal microscopy using the dyes TMRM and calcein. Seven to 10 hours
after TGFβ treatment, Smad3 (+/+) hepatocytes underwent MPT, visualized by TMRM exiting
the mitochondria and calcein entering the mitochondria with the opening of the conductance
pore. Untreated Smad3 (+/+) hepatocytes (data not shown) did not undergo the MPT nor did
Smad3 (−/−) hepatocytes treated with TGFβ (Fig. 1E).
3.2 Role of ROS in TGFβ-Mediated Apoptosis
Following TGFβ treatment, ROS generation was examined in Smad3 (+/+) hepatocytes by
fluorometric analysis for cleavage of the probe H2DCFDA. Compared to untreated Smad3 (+/
+) cells, those treated with TGFβ demonstrated a 39% to 81% increase (p<0.05) in ROS with
maximal activity between 30 min and one hour of treatment. Smad3 (−/−) hepatocytes treated
with TGFβ had no increase in ROS, but demonstrated up to a 51% decrease in ROS activity
at 60 minutes, suggesting that ROS increase after TGFβ is dependent on Smad3 (Fig. 2A).
Furthermore, ROS activity remained increased in Smad3 (+/+) hepatocytes for 4 hours (Fig.
2A).
The importance of Smad3 in TGFβ-mediated ROS increase was also investigated in Smad3
deficient JAR cells [7]. JAR cells did not increase ROS in the presence of TGFβ (Fig. 2B),
further suggesting the need of Smad3 for TGFβ-induced ROS generation.
In addition, Smad3 (+/+) hepatocytes were pretreated with the anti-oxidant, trolox (2 mM),
and ROS activity and apoptosis were assessed. Smad3 (+/+) hepatocytes pretreated with trolox
with subsequent TGFβ administration showed no increase in ROS compared to TGFβ-only
treated hepatocytes, which had a 1.38 ± 0.15-fold increase in ROS activity at 60 minutes (Fig.
2C). Apoptosis was assessed in Smad3 (+/+) hepatocytes pretreated with trolox, and only 6.4%
± 1.5% of the cells were apoptotic in response to TGFβ as compared to 55% ± 11% apoptosis
in Smad3 (+/+) hepatocytes that were not pretreated with trolox (Fig. 2D). Trolox also
decreased TGFβ-induced caspase-3 activity by 55% at 48 hours (data not shown).
Because it appeared that Smad3 is required for TGFβ-induced acute generation of ROS, we
wished to determine if this finding was dependent on protein synthesis. Smad3 (+/+)
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hepatocytes were pretreated with actinomycin D (1−10 μg/ml) or cycloheximide (10 μg/ml)
one hour before TGFβ treatment and ROS generation was determined. A dose-response study
revealed that lower concentrations of actinomycin D (1−10 μg/ml) and cycloheximide (1−10
μg/ml) did not compromise hepatocyte viability, whereas higher concentrations were cytotoxic
(data not shown). At the 10 μg/ml doses used in this study, hepatocytes were viable and multiple
previous studies show that transcription and translation are inhibited at these concentrations in
hepatocytes [18;19]. Smad3 (+/+) hepatocytes pretreated with actinomycin D prior to TGFβ
treatment did not have decreased ROS following treatment (Fig 2E). This observation
demonstrated that Smad3 transcriptional activity is not necessary for TGFβ-induced ROS (Fig.
2E). Similar findings were obtained with cycloheximide pretreatment.
In order to investigate whether a NADPH-like system is involved in Smad3-dependent ROS
increase after TGFβ treatment, ROS formation was fluorometrically evaluated in the presence
and absence of 1 μM of diphenyleneiodonium chloride (DPI), a flavoprotein inhibitor of
NADPH oxidase [20]. Pretreatment of hepatocytes with DPI prevented TGFβ-induced ROS
increase, suggesting that this system is required for TGFβ-induced ROS generation (Fig. 2F).
To demonstrate Smad3 involvement in TGFβ-induced gene transcription and assess the
function of wild-type and dominant-negative Smad3 plasmids, Smad3 hepatocytes were
transiently transfected with p3TP-Luc, a TGFβ responsive reporter plasmid that contains
multiple Smad binding elements. TGFβ treatment induced transcriptional activity of p3TP-Luc
was 6.21 ± 2.08-fold in TGFβ-treated Smad3 (+/+) hepatocytes as compared with untreated
cells (Fig. 2G). Smad3 (−/−) hepatocytes showed a decreased response as compared to Smad3
(+/+) hepatocytes to transfection with the reporter plasmid.
Transfection of Smad3 (+/+) hepatocytes with a dominant-negative Smad3 (DN) plasmid
inhibited transcriptional activity in response to TGFβ treatment (Fig. 2G). In Smad3 (−/−)
hepatocytes, transfection with Smad3 WT-plasmid transfection increased TGFβ responsive
reporter activity compared to untreated and TGFβ treated Smad3 (−/−) hepatocytes (Fig. 2G).
3.3 DN-Smad3 Plasmid Inhibits TGFβ-Induced Apoptosis in Smad3 (+/+) Hepatocytes
To confirm that the TGFβ apoptotic signaling pathway is Smad3 dependent, Smad3 (+/+)
hepatocytes were transiently transfected with a DN-Smad3 expressing plasmid and apoptosis
was subsequently determined. After 48 hours of TGFβ treatment, Smad3 (+/+) hepatocytes
transiently transfected with the DN-Smad3 plasmid demonstrated 22.7% ± 6.1% apoptosis
versus 56.6% ± 15.8% apoptosis in those cells transiently transfected with the control vector
(Fig. 3A).
Furthermore, Smad3 (+/+) hepatocytes transiently transfected with the DN-Smad3 plasmid
blocked important mediators of the TGFβ apoptotic pathway including ROS generation and
occurrence of MPT. Smad3 (+/+) hepatocytes transfected with the control vector and treated
with TGFβ had a 56% increase in ROS activity at 60 minutes, whereas Smad3 (+/+) hepatocytes
transfected with DN-Smad3 did not differ from controls (Fig. 3B). Moreover, the MPT, which
normally occurs between 7 and 10 hours of TGFβ treatment in Smad3 (+/+) hepatocytes was
not present through 12 hours of TGFβ treatment in hepatocytes transfected with DN-Smad3
(Fig. 3C).
3.4 WT-Smad3 Plasmid Mediates TGFβ-Induced Apoptosis in Smad3 (−/−) Hepatocytes
To determine if Smad3 replacement was sufficient enough to permit TGFβ-induced apoptosis
in Smad3 (−/−) hepatocytes, these cells were transiently transfected with WT-Smad3 plasmid
and apoptosis was then determined. Smad3 (−/−) hepatocytes transiently transfected with WT-
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Smad3 plasmid alone had 22.7% ± 7.3% apoptosis after 48 hours, while the addition of
TGFβ increased the percent of apoptosis to 40.6% ± 4.6% (Fig. 4A).
To determine if ROS and MPT were altered by the WT-Smad3 plasmid, Smad3 (−/−)
hepatocytes were transiently transfected with WT-Smad3 and ROS, and MPT was
subsequently assessed. As expected, Smad3 (−/−) hepatocytes did not generate increased ROS
activity with TGFβ treatment, but the introduction of WT-Smad3 into hepatocytes treated with
TGFβ increased ROS activity by 55% as compared to cells treated with the control vector (Fig.
4B).
Similar to non-transfected Smad3 (−/−) hepatocytes, those cells transiently transfected with
the control vector did not undergo MPT with or without TGFβ treatment (data not shown).
However, TGFβ treatment for 12 hours induced MPT in Smad3 (−/−) hepatocytes transfected
with the WT-Smad3 plasmid, but cells treated with TGFβ only did not exhibit the MPT (Fig.
4C).
4. Discussion
Hepatocyte apoptosis is one of the mechanisms by which TGFβ regulates liver growth.
Alterations in the TGFβ signal transduction pathway, including Smad defects, may result in
carcinogenic mutations. Examining the role of the Smad protein family in TGFβ-induced
apoptosis may provide further insight into the growth capabilities of abnormal cells and
cancers. In the present study, a direct relationship between Smad3 and mediators of the
TGFβ apoptotic pathway were examined in primary murine hepatocytes from Smad3 (+/+)
and Smad3 (−/−) mice. These data support a critical role for Smad3 in TGFβ-induced apoptosis
because Smad3 (−/−) hepatocytes failed to undergo programmed cell death. Furthermore,
Smad3 appears to be critical in the initiation of apoptosis since caspase-8 activity was absent
in the Smad3 (−/−) hepatocytes. Smad3 (−/−) hepatocytes also failed to generate ROS, a
necessary intermediary for TGFβ-induced hepatocyte apoptosis. Importantly, these early
events were transcription independent and could be reversed by introducing Smad3 into Smad3
(−/−) hepatocytes with a wild-type Smad3 expressing plasmid. Therefore, Smad3 appears to
play a crucial role in the TGFβ-induced hepatocyte apoptotic pathway.
Previous work has demonstrated that TGFβ-induced hepatocyte apoptosis occurs in a ROS,
MPT, and caspase-dependent apoptotic pathway that has no clear association with the Smad
signal transduction pathway [5]. These experiments provide evidence that the TGFβ apoptotic
pathway is dependent on Smad3. Smad3 (+/+) hepatocytes treated with TGFβ displayed ROS
generation, MPT, caspase activation, and apoptosis while Smad3 (−/−) hepatocytes did not. In
addition, Smad3 (+/+) hepatocytes transiently transfected with DN-Smad3 showed decreased
apoptosis compared to controls whereas Smad3 (−/−) hepatocytes transiently transfected with
WT-Smad3 exhibited an increase in apoptosis, thus indicating that Smad3 is critical in the
TGFβ-induced apoptotic pathway. These findings are also consistent with previous studies
demonstrating a role for Smad3 in apoptosis in non-primary cell lines [2;21].
Although the necessity of Smad3 in TGFβ-induced apoptosis has been established, the
mechanism of action or point of interaction in the apoptotic pathway has not been previously
elucidated. Smad3 appears to be critical to the generation of ROS because Smad3 (−/−)
hepatocytes did not demonstrate acute generation of oxygen intermediates. Furthermore, in
JAR cells that lack Smad3, there was no generation of ROS in response to TGFβ suggesting
that Smad3 is required for ROS generation in response to this cytokine. ROS generation is an
early upstream event in TGFβ-induced apoptosis, and inhibition of ROS with trolox prevents
apoptosis, MPT, and caspase activity [5]. Oxidative stress is a known mediator of apoptosis,
including TGFβ-induced apoptosis, and to more closely exam a potential source of ROS we
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treated hepatocytes with DPI, an inhibitor of the NADPH-like oxidase system. DPI inhibited
the generation of ROS in response to TGFβ suggesting that Smad3 interacts with the NADPH-
like oxidase system to produce ROS after treatment with TGFβ. The mechanism(s) through
which Smad3 interacts with NADPH-like oxidase remain unknown, but previous work has
demonstrated that Smad2/3, NADPH-oxidase, and ERK1/2 may interact to alter ROS [22].
These findings are also supported by previous work that demonstrates the rule of the NADPH-
like oxidase system in hepatocyte ROS generation [20]. Furthermore, in TGFβ-mediated
apoptosis, ROS generation in L1210 leukemic cells occurs at 60 minutes, similar to our findings
in primary murine hepatocytes [23]. Likewise, Herrera et al. found an increase in ROS
production by confocal microscopy at 8 hours of TGFβ treatment in fetal hepatocytes [24].
Acute ROS generation is an early event (30 minutes) in this model of TGFβ-induced apoptosis.
Importantly, this work also demonstrates that ROS generation 30−60 minutes following
TGFβ treatment is independent of new protein synthesis. Our experiments with actinomycin
D and cycloheximide demonstrate that the early ROS peak after TGFβ treatment persists with
inhibition of new protein synthesis. This finding differs from the previous work of other authors
[10;11], which demonstrates that ROS production required protein synthesis. However, these
two studies examined ROS generation from 4−16 hours after treatment, and this time lag may
explain, in part, why the current study differs from the previously published work. Additional
work in our laboratory demonstrates that new protein synthesis is not required for early
TGFβ mediated transcriptional activation. However, protein synthesis is required for sustained
TGFβ induced Smad3 expression. Nonetheless, the time course of apoptosis is long and likely
dependent on additional factors. In addition, because MPT occurs at ∼10 hours and caspase
activation is not evident until 36−48 hours after treatment; other factors are likely to be
necessary for the convergence of ROS generation, MPT, and caspase activation. Therefore,
the time lapse between ROS generation, MPT, and cytochrome c release may be due to
mitochondrial-dependent events.
5. Conclusion
In summary, Smad3 is a primary mediator of TGFβ-induced hepatocyte apoptosis through
ROS generation with subsequent mitochondrial depolarization and caspase activation. Smad3-
dependent activities do not require protein synthesis, and ROS generation appears to be through
a NADPH-like oxidase pathway. These findings suggest interactions between the traditional
apoptotic pathway including receptor activation, mitochondrial depolarization, and caspase
activation. The TGFβ-induced Smad signal transduction pathways are complex and may
involve direct interactions rather than transcriptionally-regulated events.
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Smad3 (+/+) or (−/−) hepatocytes were treated with or without TGFβ (5 ng/ml), TNFα (30 ng/
ml), or actinomycin D (1 μg/ml). Apoptosis was determined morphologically by propidium
iodide staining and biochemically by caspase activity. (A) Smad3 (+/+) and (−/−) hepatocytes
were untreated or treated with TGFβ and morphology was assessed at 48 hours by PI staining.
Smad3 (+/+) hepatocytes displayed condensed nuclei and cell shrinkage consistent with
apoptosis whereas Smad3 (−/−) hepatocytes appeared similar to controls. (B) Hepatocyte
apoptosis was quantified by counting the number of condensed nuclei per 5 high power fields
and expressed as percent condensed nuclei over time. Smad3 (+/+) hepatocytes had
significantly increased (*p<0.05) apoptosis at 48 hours of TGFβ treatment compared to Smad3
(−/−) hepatocytes. (C) Apoptosis was assessed by caspase activity assay for caspase-3 and
caspase-8 activation expressed as fold increase over control at 24, 36, and 48 hours. Caspase-3
activity was increased significantly (*p<0.05) in Smad3 (+/+) hepatocytes compared to Smad
(−/−) hepatocytes at 36 hours. Caspase-8 activity demonstrated a similar pattern, but was less
robust. (D) To determine if inhibition of apoptosis in Smad3 (−/−) mice was specific for
TGFβ, Smad3 (+/+) and (−/−) hepatocytes were treated with or without TNFα and actinomycin
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D (ActD) and apoptosis was determined. Both Smad3 (+/+) hepatocytes and Smad3 (−/−)
hepatocytes readily underwent TNFα-induced apoptosis (no significant difference). (E) To
determine if Smad3 (+/+) and (−/−) hepatocytes underwent MPT in response to TGFβ
treatment; these hepatocytes were loaded with the fluorophores TMRM (red) and calcein
(green). After 10 hours of treatment, Smad3 (+/+) hepatocytes demonstrated mitochondrial
loss of TMRM and uptake of calcein consistent with the MPT. Smad3 (−/−) hepatocytes,
however, maintained mitochondrial integrity indicating resistance to TGFβ-induced MPT.
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The effect of ROS generation in Smad3 (+/+) and (−/−) was determined from 30−240 minutes
following TGFβ treatment. (A) Smad3 (+/+) hepatocytes demonstrated consistently increased
ROS activity compared to Smad3 (−/−) hepatocytes (*p<0.05 for the curves). A consistent
burst of ROS activity was noted at 30−60 minutes after treatment, but the magnitude of the
activity was variable. (B) ROS generation in Smad3 deficient JAR cells was fluorometrically
determined. In contrast to Smad (+/+) hepatocytes, JAR cells did not increase ROS after
TGFβ treatment (p<0.05). (C) Smad3 (+/+) hepatocytes were treated with the antioxidant,
trolox, alone or in combination with TGFβ to determine if TGFβ-induced ROS activity could
be inhibited. At 60 minutes, TGFβ treatment increased ROS generation significantly, and
pretreatment with trolox attenuated markedly (*p<0.05) this burst of activity compared to
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TGFβ alone. (D) To determine the effect of inhibition of TGFβ-induced ROS on apoptosis,
Smad3 (+/+) hepatocytes were treated with trolox, TGFβ, or trolox and TGFβ and apoptosis
was assessed morphologically at 48 hours. Inhibition of ROS generation by trolox decreased
significantly (*p<0.05) TGFβ-induced apoptosis. (E) The dependence of Smad3-induced ROS
generation on transcription and translation was determined by pretreating Smad3 (+/+)
hepatocytes with either actinomycin D (10 μg/ml) or cycloheximide (10 mg/ml) and measuring
H2DCFDA cleavage at 60 minutes. Neither actinomycin D nor cycloheximide decreased early
ROS generation suggesting that gene transcription or protein synthesis is not required for ROS
activity following TGFβ treatment. (F) The involvement of NADPH oxidase-like system in
ROS increase was investigated in the presence of diphenyleneiodonium chloride (DPI).
Hepatocytes were treated with 1 μM of DPI for 30 min prior to TGFβ administration and ROS
generation was determined by H2DCFDA fluorometry. DPI prevented TGFβ-induced increase
in ROS. (G) Smad3 (+/+) and (−/−) hepatocytes were transiently transfected with a TGFβ-
responsive luciferase reporter plasmid, p3TPLuc, and subsequently treated with 5 ng/ml
TGFβ. In additional experiments, following transfection of the reporter plasmid, Smad3 (+/+)
hepatocytes were transfected with a DN-Smad3 plasmid and Smad3 (−/−) hepatocytes
transfected with a WT-Smad3 plasmid and luciferase measured after stimulation with TGFβ.
Treatment of Smad3 (+/+) hepatocytes with TGFβ alone resulted in significantly increased
luciferase activity compared to Smad3 (−/−) hepatocytes. However, transfection of Smad3 (+/
+) hepatocytes with the DN-Smad3 followed by TGFβ treatment (light gray bar) decreased
markedly transcriptional activity. Conversely, transfection of Smad3 (−/−) hepatocytes with
WT-Smad3 followed by TGFβ treatment significantly increased luciferase activity (light gray
bar).
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Smad3 (+/+) hepatocytes were transiently transfected with control vector or the DN-Smad3
vector and subsequently treated with or without TGFβ prior to assessment of apoptosis, ROS
generation, and MPT. (A) Smad3 (+/+) hepatocytes treated with 5 ng/ml TGFβ following
transfection with DN-Smad3 demonstrated significantly decreased apoptosis (*p<0.05) as
compared to identical cells transfected with the control vector and treated with TGFβ. (B)
TGFβ-induced ROS in Smad3 (+/+) hepatocytes transfected with DN-Smad3 exhibited ROS
generation similar to controls. (C) The MPT was assessed by confocal microscopy in Smad3
(+/+) hepatocytes transfected with the DN-Smad3 vector and subsequently treated with
TGFβ. Transfection with DN-Smad3 inhibited the MPT following TGFβ treatment in Smad3
(+/+) hepatocytes.
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Smad3 (−/−) hepatocytes were transiently transfected with either control vector or vector
expressing WT-Smad3. Subsequently, apoptosis, ROS generation, and MPT were determined.
(A) Smad3 (−/−) hepatocytes transiently transfected with WT-Smad3 and subsequently treated
with TGFβ demonstrated significantly increased apoptosis (*p<0.05) compared to identical
cells transfected with control vector and treated with TGFβ. (B) ROS was determined in Smad3
(−/−) hepatocytes transiently transfected with WT-Smad3 and subsequently treated with
TGFβ. Transfection with the WT-Smad3 partially restored ROS generation in these
hepatocytes. (C) Smad3 (−/−) hepatocytes transiently transfected with WT-Smad3 and treated
with TGFβ showed MPT 12 hours following treatment. Control transfected Smad3 (−/−)
hepatocytes treated with TGFβ failed to undergo to MPT.
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